Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-RSTAP
NCT07423910Recruiting
- Sponsor
- Tampere University Hospital
- Start
- Jul 2025
- Primary completion
- Jan 2028
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, double-blind trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (4 arms), sponsored by Tampere University Hospital. Primary endpoint: Total cumulative opioid consumption. Started Jul 2025; status: recruiting.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07423910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07423910.